Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medtronic (MDT – Research Report), Icon (ICLR – Research Report) and Crispr Therapeutics AG (CRSP – Research Report).
Medtronic (MDT)
Barclays analyst Matt Miksic maintained a Buy rating on Medtronic yesterday and set a price target of $104.00. The company’s shares closed last Wednesday at $85.90.
According to TipRanks.com, Miksic is a 5-star analyst with an average return of
Medtronic has an analyst consensus of Moderate Buy, with a price target consensus of $93.80, implying an 8.4% upside from current levels. In a report issued on February 13, Bank of America Securities also maintained a Buy rating on the stock with a $100.00 price target.
See today’s best-performing stocks on TipRanks >>
Icon (ICLR)
In a report released yesterday, Luke Sergott from Barclays maintained a Buy rating on Icon, with a price target of $325.00. The company’s shares closed last Wednesday at $284.70, close to its 52-week high of $296.68.
According to TipRanks.com, Sergott is a 1-star analyst with an average return of
Currently, the analyst consensus on Icon is a Strong Buy with an average price target of $318.38.
Crispr Therapeutics AG (CRSP)
Barclays analyst Gena Wang maintained a Hold rating on Crispr Therapeutics AG yesterday and set a price target of $80.00. The company’s shares closed last Wednesday at $82.41, close to its 52-week high of $90.18.
According to TipRanks.com, Wang is a 5-star analyst with an average return of
Crispr Therapeutics AG has an analyst consensus of Moderate Buy, with a price target consensus of $85.25, implying a 3.3% upside from current levels. In a report issued on February 14, Wolfe Research also initiated coverage with a Hold rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MDT:
